Spelling suggestions: "subject:"3structure – activity relationship"" "subject:"1structure – activity relationship""
11 |
Synthesis of aldehyde-functionalized building blocks and their use for the cyclization of peptides : applications to Angiotensin II /Johannesson, Petra, January 2002 (has links)
Diss. (sammanfattning) Uppsala : Univ., 2002. / Härtill 4 uppsatser.
|
12 |
Studies on oxysterols : origins, properties and roles /Meaney, Steve, January 2003 (has links)
Diss. (sammanfattning) Stockholm : Karol. inst., 2003. / Härtill 6 uppsatser.
|
13 |
Characterization of biomolecular interactions using a multivariate approach /Andersson, Karl, January 2004 (has links)
Diss. (sammanfattning) Uppsala : Univ., 2004. / Härtill 5 uppsatser.
|
14 |
Antiplasmin the main plasmin inhibitor in blood plasma : studies on structure-function relationships /Wang, Haiyao, January 2005 (has links)
Diss. (sammanfattning) Stockholm : Karolinska institutet, 2005. / Härtill 4 uppsatser.
|
15 |
Heme biosynthesis: structure-activity studies of murine ferrochelatase /Shi, Zhen. January 2006 (has links)
Dissertation (Ph.D.)--University of South Florida, 2006. / Includes vita. Includes bibliographical references. Also available online.
|
16 |
2,4-Disubstituted Quinazolines with Antileishmanial or Antibacterial ActivityBarber, Megan Marie 01 January 2015 (has links)
Herein 47 2,4-disubstituted quinazolines were synthesized and tested against Leishmania donovani intracellular amastigotes. A structure-activity relationship was conducted and lead to the identification of quinazolines with EC50s in the single digit and high nanomolar range with favorable antileishmanial selectivity indexes. Quinazoline 2.6 and 2.31 underwent in vivo efficacy studies in murine models of visceral leishmaniasis, reducing liver parasitemia by 12 % and 24 %, respectively, when given by the intraperitoneal route at 15 mg/kg/day x 5 days. The antileishmanial efficacy and easy of synthesis make the 2,4-disubstituted quinazoline compound series a suitable platform for the future development of antileishmanial agents.
A similar series of 50 N2,N4-disubstituted quinazoline-2,4-diamines has also been synthesized and tested against multi-drug resistant strains of Acinetobacter baumannii. Quinazolines with MICs in the single digit micromolar range were identified within the structure-activity relationship. The observed potencies of the top compounds and the easy of synthesis lend to the further investigation of in vivo efficacy studies and could be considered a suitable platform for the future development of anti-bacterial agents against A. baumannii.
|
17 |
Potent Human Uric Acid Transporter 1 Inhibitors: In Vitro and in Vivo Metabolism and Pharmacokinetic StudiesWempe, Michael F., Lightner, Janet W., Miller, Bettina, Iwen, Timothy J., Rice, Peter J., Wakui, Shin, Anzai, Naohiko, Jutabha, Promsuk, Endou, Hitoshi 07 November 2012 (has links)
Human uric acid transporter 1 (hURAT1; SLC22A12) is a very important urate anion exchanger. Elevated urate levels are known to play a pivotal role in cardiovascular diseases, chronic renal disease, diabetes, and hypertension. Therefore, the development of potent uric acid transport inhibitors may lead to novel therapeutic agents to combat these human diseases. The current study investigates small molecular weight compounds and their ability to inhibit 14C-urate uptake in oocytes expressing hURAT1. Using the most promising drug candidates generated from our structure-activity relationship fndings, we subsequently conducted in vitro hepatic metabolism and pharmacokinetic (PK) studies in male Sprague-Dawley rats. Compounds were incubated with rat liver microsomes containing cofactors nicotinamide adenine dinucleotide phosphate and uridine 5′-diphosphoglucuronic acid. In vitro metabolism and PK samples were analyzed using liquid chromatography/mass spectrometry-mass spectrometry methods. Independently, six different inhibitors were orally (capsule dosing) or intravenously (orbital sinus) administered to fasting male Sprague-Dawley rats. Blood samples were collected and analyzed; these data were used to compare in vitro and in vivo metabolism and to compute noncompartmental model PK values. Mono-oxidation (Phase I) and glucuronidation (Phase II) pathways were observed in vitro and in vivo. The in vitro data were used to compute hepatic intrinsic clearance, and the in vivo data were used to compute peak blood concentration, time after administration to achieve peak blood concentration, area under the curve, and orally absorbed fraction. The experimental data provide additional insight into the hURAT1 inhibitor structure-activity relationship and in vitro-in vivo correlation. Furthermore, the results illustrate that one may successfully prepare potent inhibitors that exhibit moderate to good oral bioavailability.
|
18 |
Structure-activity relationship studies in medicinal chemistry and drug designSrivastava, Sanjay January 1992 (has links)
No description available.
|
19 |
The importance of scaling in data mining for toxicity prediction.Mazzatorta, P., Benfenati, E., Neagu, Daniel, Gini, G. January 2002 (has links)
No / While mining a data set of 554 chemicals in order to extract information on their toxicity value, we faced the problem of scaling all the data. There are numerous different approaches to this procedure, and in most cases the choice greatly influences the results. The aim of this paper is 2-fold. First, we propose a universal scaling procedure for acute toxicity in fish according to the Directive 92/32/EEC. Second, we look at how expert preprocessing of the data effects the performance of qualitative structure-activity relationship (QSAR) approach to toxicity prediction.
|
20 |
Structure-Activity Relationship Studies of Imidazo[4,5-b]pyrazine Derivatives as Mitochondrial Uncouplers and their Potential in the Treatment of ObesitySantiago-Rivera, Jose Antonio 16 December 2021 (has links)
Mitochondrial uncouplers have the capacity of passively shuttling protons from the mitochondrial intermembrane space to the mitochondrial matrix, independent of ATP synthase. This results in the disruption of oxidative phosphorylation and increased rate of metabolism as a counter action from the mitochondria. Therefore, small molecule mitochondrial uncouplers have potential for the treatment of obesity, diabetes, non-alcoholic fatty liver disease (NAFLD), neurodegenerative disorders, amongst others.
A one-pot method for the synthesis of 1H-imidazo[4,5-b]pyrazines from [1,2,5]oxadiazolo[3,4-b]pyrazines is herein disclosed. In the presence of Fe, Yb(OTf)3, and the desired electrophile partner, in situ reduction of the oxadiazole fragment followed by cyclization afforded imidazolopyrazines in moderate to good yields. The selection of different orthoesters as electrophiles also allowed functionalization on the 2-position of the imidazole ring. This new method was used to synthesize 1H-imidazo[4,5-b]pyrazines to perform structure-activity relationship studies. Thus, a library of 75 compounds was synthesized and characterized for mitochondrial uncoupling activity. The biological activity of the compounds was demonstrated in oxygen consumption rate assays affording potent mitochondrial uncouplers. The method was further applied to the synthesis of 5-alkoxy-2-(trifluoromethyl)-1H-imidazo[4,5-b]pyrazin-6-amines, with over 50 derivatives synthesized. A structure-activity relationship study was performed using a variety of substituents to fine-tune the scaffold's potency. The installation of a methoxy group at the 5-position of the scaffold resulted in the discovery of compound 4.3.20, which exhibited the best activity with an EC50 of 3.6 ± 0.4 μM in rat L6 myoblasts and a half-life of 4.4 h in mice. Compound 4.3.20 displayed potential as an anti-obesity agent in a mouse model with an effective dose of 50 mg kg-1 without changes in food intake or lean mass. Tissue distribution studies revealed predominance in the liver and both white and brown adipose tissue. In addition, 4.3.20 improved serum markers of insulin sensitivity and hyperlipidemia such as insulin, glucose, triglycerides, cholesterol, and HOMA-IR. Taken together, compound 4.3.20 and related mitochondrial uncouplers show promise for further development in the treatment of obesity and other diseases. / Doctor of Philosophy / The mitochondria, which is an organelle within our cells, is where all the nutrients ingested in the form of food are metabolized, and either used for energy or stored as fat if they are not used. The latter is the main cause of obesity, carrying with it a myriad other comorbidities, such as high blood pressure, heart disease, diabetes, certain types of cancer. Obesity has become a great concern with an incidence of 42% in the US.
Mitochondrial uncouplers are molecules that target the mitochondria with a mechanism of action of converting some of the energy ingested in the form of nutrients to be lost as heat instead of being stored as fat. The potential result is a regulated form of weight-loss.
Herein, we developed a method for the synthesis of a novel mitochondrial uncoupler scaffold and disclose the mitochondrial uncoupler activity of over 150 molecules. In particular, compound 4.3.20 was tested in an obesity mouse model and was shown to induce fat loss with mice fed a high fat diet. Our investigations support potential use of mitochondrial uncouplers as a mechanism for the treatment and prevention of obesity and other metabolic diseases.
|
Page generated in 0.139 seconds